A Single Arm Phase I-II Multicenter Trial With Avelumab Plus Autologous Dendritic Cell Vaccine in Pre-treated Mismatch Repair-proficient (MSS) Metastatic Colorectal Cancer Patients

Trial Profile

A Single Arm Phase I-II Multicenter Trial With Avelumab Plus Autologous Dendritic Cell Vaccine in Pre-treated Mismatch Repair-proficient (MSS) Metastatic Colorectal Cancer Patients

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Oct 2017

At a glance

  • Drugs Avelumab (Primary) ; Dendritic cell vaccines
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AVEVAC
  • Most Recent Events

    • 16 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 1 Dec 2017.
    • 17 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top